Over the last 12 months, Esperion Therapeutics insiders reported no purchases and 10 sales totaling $203K across SEC Form 4 filings.
Scroll the table sideways for price, value and marks.
| Date | Insider | Type | Shares | Avg price | Value | Δ stake | Marks |
|---|---|---|---|---|---|---|---|
| Jul 13, 2026 | Hoffman Robert E.D | ▽ Sale to issuer | 85,153 | — | — | -100% | — |
| Jul 13, 2026 | Shepard JayD | ▽ Sale to issuer | 164,472 | — | — | -100% | — |
| Jul 13, 2026 | Fischer Seth H. Z.D | ▽ Sale to issuer | 141,023 | — | — | -100% | — |
| Jul 13, 2026 | THOMPSON JOHN CRAIGD | ▽ Sale to issuer | 79,873 | — | — | -100% | — |
| Jul 13, 2026 | Harlow John B. Jr.Chief Commercial Officer · O | ▽ Sale to issuer | 424,536 | — | — | -100% | — |
| Jul 13, 2026 | Looker BenjaminChief Legal Officer · O | ▽ Sale to issuer | 667,524 | — | — | -100% | — |
| Jul 13, 2026 | Halladay BenjaminChief Financial Officer · O | ▽ Sale to issuer | 705,410 | — | — | -100% | — |
| Jul 13, 2026 | Koenig Sheldon L.President and CEO · O·D | ▽ Sale to issuer | 2,121,094 | — | — | -100% | — |
| Jun 17, 2026 | Koenig Sheldon L.President and CEO · O·D | ▼ Sale | 53,588 | $3.16 | $169K | -2.5% | — |
| Jun 17, 2026 | Halladay BenjaminChief Financial Officer · O | ▼ Sale | 10,773 | $3.16 | $34K | -1.5% | — |
Corporate insiders — officers, directors and 10%+ owners — must report their trades to the SEC on Form 4 within two business days. We group each filing's transactions into one economic event (a laddered 10b5-1 sale is one event, not 25 rows), flag pre-arranged plans and late filings, and link every event to its AI-scored article in the $ESPR feed.